ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
   Wendy

2. Surname (Last Name)  
   Steagall

3. Date  
   16-January-2019

4. Are you the corresponding author?  
   Yes  No

5. Manuscript Title  
   Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis

6. Manuscript Identifying Number (if you know it)  
   126703-INS-RG-TR-2

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest?  Yes  No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☐ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Steagall has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
   Mario

2. Surname (Last Name)  
   Stylianou

3. Date  
   16-January-2019

4. Are you the corresponding author?  
   □ Yes  ✔ No  
   Corresponding Author's Name  
   Wendy Steagal

5. Manuscript Title  
   Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis

6. Manuscript Identifying Number (if you know it)  
   126703-INS-RG-TR-2

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  
Are there any relevant conflicts of interest?  
   □ Yes  ✔ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.  
Are there any relevant conflicts of interest?  
   □ Yes  ✔ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  
   □ Yes  ✔ No
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☐ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Stylianou has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
   Gustavo

2. Surname (Last Name)  
   Pacheco

3. Date  
   16-January-2019

4. Are you the corresponding author?  
   [ ] Yes  [ ] No

5. Manuscript Title  
   Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis

6. Manuscript Identifying Number (if you know it)  
   126703-INS-RG-TR-2

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  
Are there any relevant conflicts of interest?  
   [ ] Yes  [ ] No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.  
Are there any relevant conflicts of interest?  
   [ ] Yes  [ ] No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  
   [ ] Yes  [ ] No
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Pacheco has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
   Joel

2. Surname (Last Name)  
   Moss

3. Date  
   16-January-2019

4. Are you the corresponding author?  
   ✓ Yes  
   □ No

5. Manuscript Title  
   Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis

6. Manuscript Identifying Number (if you know it)  
   126703-INS-RG-TR-2

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  
Are there any relevant conflicts of interest?  
   □ Yes  
   ✓ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.  
Are there any relevant conflicts of interest?  
   □ Yes  
   ✓ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  
   □ Yes  
   ✓ No
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☐ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Moss has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis
Wendy K. Steagall, Mario Stylianou, Gustavo Pacheco-Rodriguez, and Joel Moss

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><em>(a)</em> Indicate the study’s design with a commonly used term in the title or the abstract&lt;br&gt;<em>(b)</em> Provide in the abstract an informative and balanced summary of what was done and what was found</td>
</tr>
<tr>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported</td>
</tr>
<tr>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses</td>
</tr>
<tr>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
</tr>
<tr>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
</tr>
<tr>
<td>6</td>
<td><em>(a)</em> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up&lt;br&gt;<em>(b)</em> For matched studies, give matching criteria and number of exposed and unexposed</td>
</tr>
<tr>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
</tr>
<tr>
<td>8*</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
</tr>
<tr>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
</tr>
<tr>
<td>10</td>
<td>Explain how the study size was arrived at</td>
</tr>
<tr>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
</tr>
<tr>
<td>12</td>
<td><em>(a)</em> Describe all statistical methods, including those used to control for confounding&lt;br&gt;<em>(b)</em> Describe any methods used to examine subgroups and interactions&lt;br&gt;<em>(c)</em> Explain how missing data were addressed&lt;br&gt;<em>(d)</em> If applicable, explain how loss to follow-up was addressed&lt;br&gt;<em>(e)</em> Describe any sensitivity analyses</td>
</tr>
<tr>
<td>13*</td>
<td><em>(a)</em> Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed&lt;br&gt;<em>(b)</em> Give reasons for non-participation at each stage&lt;br&gt;<em>(c)</em> Consider use of a flow diagram</td>
</tr>
<tr>
<td>14*</td>
<td><em>(a)</em> Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders&lt;br&gt;<em>(b)</em> Indicate number of participants with missing data for each variable of interest&lt;br&gt;<em>(c)</em> Summarise follow-up time (eg, average and total amount)</td>
</tr>
<tr>
<td><strong>Outcome data</strong> ✓</td>
<td>15* Report numbers of outcome events or summary measures over time</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Main results</strong> ✓</td>
<td>16 <em>(a)</em> Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</td>
</tr>
<tr>
<td></td>
<td><em>(b)</em> Report category boundaries when continuous variables were categorized</td>
</tr>
<tr>
<td></td>
<td><em>(c)</em> If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</td>
</tr>
<tr>
<td><strong>Other analyses</strong> ✓</td>
<td>17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</td>
</tr>
</tbody>
</table>

**Discussion**

| **Key results** ✓  | 18 Summarise key results with reference to study objectives |
| **Limitations** ✓  | 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| **Interpretation** ✓ | 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| **Generalisability** ✓ | 21 Discuss the generalisability (external validity) of the study results |

**Other information**

| **Funding** ✓ | 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |

*Give information separately for exposed and unexposed groups.

NIH Publishing Agreement & Manuscript Cover Sheet

By signing this Cover Sheet, the Author, on behalf of NIH, agrees to the provisions set out below, which modify and supersede, solely with respect to NIH, any conflicting provisions that are in the Publisher’s standard copyright agreement (the “Publisher’s Agreement”). If a Publisher’s Agreement is attached, execution of this Cover Sheet constitutes an execution of the Publisher’s Agreement, subject to the provisions and conditions of this Cover Sheet.

1. Indemnification. No indemnification or “hold harmless” obligation is provided by either party.

2. Governing Law. This agreement will be governed by the law of the court in which a claim is brought.

3. Copyright. Author’s contribution to the Work was done as part of the Author’s official duties as a NIH employee and is a Work of the United States Government. Therefore, copyright may not be established in the United States. 17 U.S.C. § 105. If Publisher intends to disseminate the Work outside of the U.S., Publisher may secure copyright to the extent authorized under the domestic laws of the relevant country, subject to a paid-up, nonexclusive, irrevocable worldwide license to the United States in such copyrighted work to reproduce, prepare derivative works, distribute copies to the public and perform publicly and display publicly the work, and to permit others to do so.

4. No Compensation. No royalty income or other compensation may be accepted for work done as part of official duties. The author may accept for the agency a limited number of reprints or copies of the publication.

5. NIH Representations. NIH represents to the Publisher that the Author is the sole author of the Author’s contribution to the Work and that NIH is the owner of the rights that are the subject of this agreement; that the Work is an original work and has not previously been published in any form anywhere in the world; that to the best of NIH’s knowledge the Work is not a violation of any existing copyright, moral right, database right, or of any right of privacy or other intellectual property, personal, proprietary or statutory right; that where the Author is responsible for obtaining permissions or assisting the Publishers in obtaining permissions for the use of third party material, all relevant permissions and information have been secured; and that the Work contains nothing misleading, obscene, libelous or defamatory or otherwise unlawful. NIH agrees to reasonable instructions or requirements regarding submission procedures or author communications, and reasonable ethics or conflicts of interest disclosure requirements unless they conflict with the provisions of this Cover Sheet.

6. Disclaimer. NIH and the Author expressly disclaim any obligation in Publisher’s Agreement that is not consistent with the Author’s official duties or the NIH mission, described at http://www.nih.gov/about/. NIH and the Author do not disclaim obligations to comply with a Publisher’s conflict of interest policy so long as, and to the extent that, such policy is consistent with NIH’s own conflict of interest policies.

7. For Peer-Reviewed Papers to be Submitted to PubMed Central. The Author is a US government employee who must comply with the NIH Public Access Policy, and the Author or NIH will deposit, or have deposited, in NIH’s PubMed Central archive, an electronic version of the final, peer-reviewed manuscript upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication. The Author and NIH agree (notwithstanding Paragraph 3 above) to follow the manuscript deposition procedures (including the relevant embargo period, if any) of the publisher so long as they are consistent with the NIH Public Access Policy.

8. Modifications. PubMed Central may tag or modify the work consistent with its customary practices and with the meaning and integrity of the underlying work.

The NIH Deputy Director for Intramural Research, Michael Gottesman, M.D., approves this publishing agreement and maintains a single, signed copy of this text for all works published by NIH employees, and contractors and trainees who are working at the NIH. No additional signature from Dr. Gottesman is needed.

Author’s name: Joel Moss

Author’s Institute or Center: NHLBI

Name of manuscript/work: Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymph

Name of publication: JCI Insight

Author’s signature

Date, 2/29/2008

NIH OGC August 2008